Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;41(8):813-818.
doi: 10.15537/smj.2020.8.25184.

Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia

Salwa A Alhemyadi  1 , Mamoun Elawad, Konstantinos Fourtounas, Zakaria Abdrabbou, Bellalah Alaraki, Siddeg Younis, Zahir Nawaz, Salem Alqurashi, Sarar Mohamed
Affiliations

Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia

Salwa A Alhemyadi et al. Saudi Med J. 2020 Aug.

Abstract

Objectives: To determine the prevalence of Fabry disease (FD) among Saudi patients on hemodialysis.

Methods: This prospective study was conducted in 3 major hospitals in the Kingdom of Saudi Arabia (KSA). All adult patients (greater than 18 years old) attending the dialysis unit who have end-stage renal disease (ESRD) and on hemodialysis were included. Known patients with FD and those who refused to participate in the study were excluded. All eligible patients were screened for FD using dry blood spot (DBS) for alpha-galactosidase A (α-Gal A). A positive DBS (enzyme activity less than 40%) was followed by another con rmatory enzyme assay. When the second DBS sample was also positive (enzyme activity less than 40%), a Sanger sequencing of the GLA gene was performed.

Results: A total of 619 patients with ESRD and on hemodialysis were screened for FD using DBS for α-Gal A enzyme level. Enzymatic activity was below 40% in 11 samples. On retesting, 3 females had less than 20% enzymatic activity suggesting FD. Sanger sequencing of these 3 females showed the variant c.1055C greater than G (p.Ala352Gly) confirming the diagnosis of FD. Family screening of one of these 3 patients revealed one asymptomatic female carrying the same variant.

Conclusion: The prevalence of FD in this cohort was 4.8 per 1000 patients. Screening of Fabry patients with ESRD seems to be a cost-effective strategy. Furthermore, relatives of the patients identified by screening enhances this screening strategy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Family pedigree of patient 1.
Figure 2
Figure 2
Family pedigree of patient 2.
Figure 3
Figure 3
Family pedigree of patient 3.
See this image and copyright information in PMC

References

    1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. - PMC - PubMed
    1. HGMD. The human gene mutation database [Internet] 2007. [[Accessed 2020 March 24th]]. Available from http://www.hgmd.cf.ac.uk/ac/index.php .
    1. Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, et al. Functional and clinical consequences of novel α-Galactosidase a mutations in Fabry disease. Hum Mutat. 2016;37:43–51. - PubMed
    1. van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RHL, Linthorst GE, et al. A systematic review on screening for Fabry disease:prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51:1–9. - PubMed
    1. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira J, Young SP, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta. 2010;411:1906–1914. - PubMed